Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data sources
1.5.1 Primary
1.5.2 Secondary
1.5.2.1 Paid sources
1.5.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of pulmonary fibrosis
3.2.1.2 Increasing advancements in biomarker discovery technologies
3.2.1.3 Rising government initiatives and policies
3.2.1.4 Increasing use of biomarkers
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost associated with biomarker tests and diagnostics
3.2.2.2 Stringent regulatory scenario
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
3.8 Future market trends
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
Chapter 5 Market Estimates and Forecast, By Test Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Blood test
5.2.1 C-reactive protein test
5.2.2 Antibody testing kits
5.2.2.1 Antinuclear antibodies (ANA) test
5.2.2.2 Anti-CCP antibody test
5.2.3 ESR test and CBC
5.2.4 Pulmonary function test
5.2.5 Imaging test
5.2.5.1 X-rays scans
5.2.5.2 HRCT scans
5.2.6 Lung biopsy
5.2.7 Other test types
Chapter 6 Market Estimates and Forecast, By Indication, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Idiopathic pulmonary fibrosis (IPF)
6.3 Rheumatoid arthritis interstitial lung disease (RA-ILD)
6.4 Drug-induced pulmonary fibrosis
6.5 COVID-19-related pulmonary fibrosis
6.6 Pneumoconiosis
6.7 Sarcoidosis
6.8 Other indications
Chapter 7 Market Estimates and Forecast, By End-User, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals
7.3 Specialty clinics
7.4 Diagnostic laboratories
7.5 Research & academic institutes
7.6 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Biocartis NV
9.2 Biogen Inc.
9.3 Bristol-Myers Squibb Company
9.4 F. Hoffman-La Roche Ltd
9.5 Galapagos NV
9.6 Lung Therapeutics, Inc.
9.7 Myriad Genetics, Inc.
9.8 OptiKira LLC
9.9 Respivant Sciences GmbH
9.10 Veracyte, Inc.
